Senti Biosciences Inc. (SNTI), which shared some promising initial clinical data for its lead drug candidate, SENTI-202, last December, is gearing up to release additional data this year.
SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy that acts by targeting cells expressing receptor type tyrosine-protein kinase (FLT3) and cells expressing myeloid cell surface antigen (CD33). CD33 and/or FLT3 are expressed in roughly 95% of acute myeloid leukemia (AML) patients.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.